NOTCH3 and chronic myelogenous leukemia, BCR-ABL1 positive: Although there was no significant difference between these two groups, NOTCH3 (0% vs. 13.6%, p = 0.214) and RELN (0% vs. 9.1%, p = 0.476) mutations were only carried by subjects who failed to achieve MMR at 12 months, suggesting CML patients with NOTCH3 and RELN mutations might have poor long-term treatment effects (Table 2).